In addition to oropharyngeal cancers, evidence suggests there may be an etiologic role for human papillomavirus (HPV) in some other head and neck cancers arising from the oral cavity and larynx. We estimated the burden of HPV16-attributable cancers of the oral cavity (ICD-O-3 site codes C02.0-C02.3, C02.9, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C05.8, C05.9, C06.0-C06.2, C06.8, C06.9) and larynx (C32.0-C32.3, C32.8, C32.9) in the United States by pooling estimates from published case studies to calculate HPV16-attributable fractions (HPV16-AFs) and applying the HPV16-AFs to 2016-2020 US Cancer Statistics data. During 2016-2020, of an average annual number of 12,612 oral cavity cancers, 3.9% (n = 497) were estimated to be attributable to HPV16. Of an average annual number of 11,170 laryngeal cancers, 2.8% (n = 309) were estimated to be attributable to HPV16. This information can improve surveillance of HPV16-attributable cancers in the US population and inform our understanding of the potential impact of HPV vaccination on cancers at these two sites.

中文翻译：

---

HPV16 在美国口腔癌和喉癌中的作用


除口咽癌外，有证据表明，人瘤病毒 （HPV） 可能在其他一些源自口腔和喉部的头颈癌中具有病因学作用。我们通过汇总已发表案例研究的估计值来计算 HPV16-AFs，并应用 HPV16-AFs，将 HPV16-AFs 应用于 2016-2020 年美国癌症统计数据。在 2016-2020 年期间，在平均每年 12,612 例口腔癌中，估计有 3.9% （n = 497） 可归因于 HPV16。在平均每年 11,170 例喉癌中，估计有 2.8% （n = 309） 可归因于 HPV16。这些信息可以改善美国人群中 HPV16 归因癌症的监测，并帮助我们了解 HPV 疫苗接种对这两个部位癌症的潜在影响。